Abstract
IMPORTANCE This research describes a method to accurately predict the onset of epileptic seizures; this will help treat patients timely, prevent future seizures, and improve outcomes.
OBJECTIVE We aimed to assess whether the phase-amplitude coupling (PAC) between infraslow activities (ISA) and high-frequency activities (HFA) increases before seizure onset.
DESIGN AND SETTING This retrospective, single-center case series included patients admitted to the neurosurgery department at Osaka University Hospital in Suita, Osaka, from July 2018 to July 2019.
PARTICIPANTS We enrolled seven patients with drug-resistant focal epilepsy who underwent intracranial electrode placement as part of a presurgical invasive electroencephalography study.
MAIN OUTCOMES AND MEASURES We comparatively analyzed the ISA, HFA, and ISA-HFA PAC in the seizure onset zone (SOZ) or non-SOZ (nSOZ) in the interictal, preictal, and ictal states.
RESULTS We recorded 15 seizures in seven patients [1 female (14%); mean (SD) age = 26 (12) years; age range, 15-47 years]. HFA and ISA were larger in the ictal states than in the interictal and preictal states. During seizures, the HFA and ISA of the SOZ were larger and earlier than those of nSOZ. In the preictal states, the ISA-HFA PAC was larger than that of the interictal states, and it began increasing at 93 seconds before the seizure onset (95% confidence interval: −116 – −71 s). There were no differences in the values and time of ISA-HFA PAC between both zones. Our phase-based analysis revealed differences between the SOZ- and nSOZ-PAC. In SOZ, the HFA amplitudes were tuned at the trough of the ISA oscillations, and in nSOZ, the HFA amplitudes were tuned at the peak of these oscillations. The receiver-operating characteristic curve showed that the ISA-HFA PAC of the SOZ showed the highest discrimination performance in the preictal and interictal states, with an area under the curve (AUC) of 0.926. However, ISA-HFA PAC was not suitable to differentiate between SOZ and nSOZ (interictal AUC = 0.555, preictal AUC = 0.691, and ictal AUC = 0.646).
CONCLUSION AND RELEVANCE This study demonstrated the novel insight that ISA-HFA PAC increases before the onset of seizures, regardless of the seizure onset zone. Our findings indicate that ISA-HFA PAC is a potential biomarker for predicting the onset of seizures and may be valuable to physicians who routinely treat epileptic patients.
Question Is phase-amplitude coupling (PAC) between infraslow activities (ISA) and high-frequency activities (HFA) a useful biomarker for seizure prediction?
Findings In this case series study on 15 focal-onset seizures in seven epileptic patients who underwent intracranial electrode placement, we found that a PAC of the ISA phase and HFA amplitude achieved significantly higher values in preictal states than in the interictal states, and ISA-HFA PAC of the seizure onset zone (SOZ) began increasing at 93 seconds before seizure onset (SO), while both HFA and ISA increased after SO. The receiver-operating characteristic curve showed that the ISA-HFA PAC of the SOZ showed the highest discrimination performance in the preictal and interictal states, with an area under the curve of 0.926.
Meaning This study demonstrates that ISA-HFA PAC can differentiate between the preictal and interictal states of a seizure, indicating that it is a potential marker for seizure prediction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Grants-in-Aid for Early-Career Scientists (KAKENHI; grant no. 18K18366), which is funded by the Japan Society for the Promotion of Science (JSPS; Tokyo, Japan).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study design was approved by the Ethics Committee of Osaka University Hospital (approval no. 19193) and informed consent was obtained using the opt-out method on our center website.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Hui Ming Khoo khoo{at}nsurg.med.osaka-u.ac.jp, Takufumi Yanagisawa tyanagisawa{at}nsurg.med.osaka-u.ac.jp, Naoki Tani n-tani{at}nsurg.med.osaka-u.ac.jp, Satoru Oshino s-oshino{at}nsurg.med.osaka-u.ac.jp, Haruhiko Kishima hkishima{at}nsurg.med.osaka-u.ac.jp, Masayuki Hirata mhirata{at}ndr.med.osaka-u.ac.jp
New eFigure was added and other eFigures were revised. New; eFigure 1 Revised; eFigure 2-4
Data Availability
All data that were generated by or analyzed in this study are available from the corresponding authors upon reasonable request and after additional ethics approvals regarding the data provision to individual institutions.
